Regencell Bioscience Holdings Limited Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Regencell Bioscience Holdings Limited
Access all reports
Regencell Bioscience Holdings Limited is a biotechnology company focused on developing traditional Chinese medicine-based treatments for neurocognitive disorders and degenerative conditions. The companyβs research aims to address conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), utilizing natural and holistic treatment approaches. Regencell's therapies are grounded in traditional medical practices, combined with modern scientific methods, to offer alternative treatment options for patients with these neurological conditions. The company is headquartered in Hong Kong, and its shares are listed on the Nasdaq.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
RGC
Country
πΊπΈ United States